A recent study from the Department of Anatomy, University of California, San Francisco, San Francisco, California, USA shows that “RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth.” This study was published in the 25 May 2015 issue of Nature cell biology (One of the best research journal in Cell biology with an Impact factor of ~20.761) by Prof. Roose JP, Depeille P and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based therapy for Intestinal cancer: PAPD5 opposses proliferative EGFR–SOS1–Ras signals and inhibits the progression of intestinal cancer via up regulation of RasGRP1
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, L., Small molecule-based therapy for Intestinal cancer: PAPD5 opposses proliferative EGFR–SOS1–Ras signals and inhibits the progression of intestinal cancer via up regulation of RasGRP1, 6/June/2015, 1.27 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Significance:
Given that (1) more than 1 million people every year worldwide are affected by Colorectal cancer; (2) the number of deaths increased from 490,000 in 1990 to 715,000 in 2010; (3) colorectal cancer is the second and third most frequent cause of cancer in women and men worldwide, respectively; (4) colorectal cancer is more common in developed countries, such as Australia, New Zealand, Europe and the US, than in developing countries; and (5) the global economic cost spent for colorectral cancer treatment is enormous, there is an urgent need to find: (1) a cheaper alternative to the existing expensive drugs; and (2) a side-effect-free natural product-based drug.
The EGFR–SOS1–Ras axis has been shown to (1) be over expressed in a number of cancers: (2) promote tumor proliferation, invasion and metastasis; and (3) promote cancer stem cell proliferation. This study suggests that PAPD5, by decreasing the expression of its target gene, it may increase the expression of RasGRP1. Thereby, it may inhibit the progression of colorectal cancer. Thus, pharmacological formulations encompassing “PAPD5 activators“ may be used to inhibit the progression of colorectal cancer.
Undisclosed information: How PAPD5 increases the expression of RasGRP1
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org